Beta Drugs share news, announcements and annual reports
NSE: BETAPharmaceuticals & BiotechnologySmall Cap
Beta Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017 · Issue price ₹85
Last close ₹1,798.40down ₹51.30 (2.77%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,849.70.
30 Oct: open ₹1,880.60, high ₹1,880.60, low ₹1,790.60
52-week range of traded prices to 30 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,000 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 23,66047.9% delivered
Beta Drugs disputes and clarifications
25 filed, newest first.
Jul 2026
22 Jul · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Jun 2026
15 Jun · Legal
The exchange asked on 12 Jun 2026
Apr 2026
7 Apr · Legal
The exchange asked on 6 Apr 2026
Jul 2025
Jun 2025
21 Jun · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Dec 2024
7 Dec · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2023
17 May · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2022
7 Feb · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 02-Feb-2022, regarding New Product Launches to drive growth for Beta Drugs. On basis of above the Company is required to clarify following:1. Date of launch;2. Whether caters to domestic/ international market;3. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.
Jan 2022
24 Jan · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 20-Jan-2022, regarding appointment of Mr. Ashutosh Shukla as Additional Director of the company. On basis of above you are required to clarify following - 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
May 2021
Apr 2021
29 Apr · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2020
16 Jun · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 12-Jun-2020, regarding "New Product Launches". On basis of above the Company is required to clarify following: 1. Whether caters to domestic/ international market; 2. Name of the countries in which the product is launched (in case of international). The response of the Company is awaited.8 Jun · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2019
8 Nov · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
May 2018
15 May · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. No Segment Reporting. The response of the Company is awaited.
Jan 2018
4 Jan · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 03-Jan-2018, regarding "Outcome of Board Meeting held on January 03, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.